Aveanna Healthcare (NASDAQ:AVAH) Insider Edwin Reisz Sells 16,602 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 16,602 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $8.18, for a total transaction of $135,804.36. Following the sale, the insider directly owned 1,338,727 shares in the company, valued at $10,950,786.86. The trade was a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Aveanna Healthcare Price Performance

Aveanna Healthcare stock opened at $8.08 on Friday. The firm has a market capitalization of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a one year low of $3.67 and a one year high of $10.32. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. The business has a fifty day moving average price of $8.92 and a 200-day moving average price of $7.49.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings data on Monday, May 22nd. The company reported $0.04 earnings per share (EPS) for the quarter. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%.The business had revenue of $450.53 million for the quarter. As a group, equities research analysts forecast that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AVAH. Jefferies Financial Group upped their target price on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Tuesday, October 28th. William Blair assumed coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Monday. Zacks Research cut Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 20th. Finally, JPMorgan Chase & Co. upgraded Aveanna Healthcare from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $6.00 to $10.00 in a research note on Thursday, September 18th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.69.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Institutional Investors Weigh In On Aveanna Healthcare

A number of large investors have recently added to or reduced their stakes in the company. Summit Partners L P bought a new stake in Aveanna Healthcare during the second quarter worth about $50,477,000. AustralianSuper Pty Ltd purchased a new position in shares of Aveanna Healthcare during the 3rd quarter valued at about $15,743,000. Vanguard Group Inc. raised its holdings in shares of Aveanna Healthcare by 34.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company’s stock valued at $35,850,000 after buying an additional 1,041,324 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in Aveanna Healthcare in the 3rd quarter worth approximately $7,922,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Aveanna Healthcare in the third quarter worth approximately $7,356,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.